Full Breakdown
Validation of Seer’s Proteograph Platform in Genomic Research
12/2/2025, 5:27:20 PM
Groundbreaking Study on Mass Spectrometry Proteomics
On December 1, 2025, Seer, Inc. (Nasdaq: SEER) announced the publication of a significant genome-wide association study (GWAS) in *Nature Genetics*. This study, led by Dr. Karsten Suhre from Weill Cornell Medicine–Qatar, alongside collaborators from Harvard Medical School/Brigham and Women’s Hospital, Seer, and TruDiagnostic, highlights the critical role of mass spectrometry in validating genetic associations for drug targets and clinical biomarkers. The research utilized Seer’s Proteograph® Product Suite to analyze approximately 1,600 blood samples, revealing that mass spectrometry validation is essential for accurate proteogenomic insights.
Key Findings and Methodology
The study involved a discovery cohort of 1,260 samples and an independent replication cohort of 325, detecting 5,753 proteins and quantifying 1,980 across participants. Researchers identified 364 protein quantitative trait loci (pQTLs) linked to protein abundance, with 102 of these replicated in the independent cohort. Notably, 35 of the replicated signals were previously unreported, expanding the understanding of genetic regulation of proteins. The Proteograph platform's mass spectrometry approach mitigated the confounding effects of affinity-based assays, which can yield erroneous signals due to changes in protein-binding sites.
Implications for Drug Discovery and Biomarker Development
The findings underscore the importance of peptide-level validation in drug discovery and biomarker development. Dr. Serafim Batzoglou, Chief Data Officer at Seer, emphasized that the Proteograph establishes reliable protein measurements that lead to novel genetic associations. This validation process enhances confidence that selected targets reflect genuine biological processes rather than technical artifacts. The study indicates that datasets relying solely on affinity reagents may contain significant inaccuracies, potentially leading to flawed causal inferences in downstream analyses.
Official Statements & Responses
Seer’s research team articulated the transformative potential of their findings, stating, “By measuring proteins directly at the peptide level, we could distinguish true biological effects from assay artifacts—yielding a more reliable map from genes to proteins to disease pathways.” This perspective aligns with the broader goal of integrating proteomics with genomics and clinical records, thereby enhancing the accuracy and utility of large-scale datasets in translational medicine.
Criticism & Opposition
While the study presents compelling evidence for the efficacy of mass spectrometry in proteomics, some critics argue that reliance on a single method may overlook the benefits of complementary approaches. They suggest that a multi-faceted strategy could provide a more comprehensive understanding of protein-gene interactions.
What's Next
The publication marks a pivotal moment for Seer as it seeks to position its Proteograph platform as a standard in population-scale proteomics. Future research will likely focus on expanding the application of mass spectrometry in clinical settings, aiming to bridge the gap between laboratory findings and real-world therapeutic outcomes.
Verbatim Quotes
- “The Proteograph platform made it possible to perform population-scale mass spectrometry proteomics with the depth and reproducibility needed for genetic association studies,” — Dr. Karsten Suhre, Weill Cornell Medicine–Qatar
- “This study demonstrates that mass spectrometry-based analysis is crucial for proteomics,” — Dr. Serafim Batzoglou, Seer, Inc.
